Developer docs
API playgroundTry for free, no card

Search company profiles

Oxford Cannabinoid Technologies

Full company profile

uuid0003efd

Namestring
Oxford Cannabinoid Technologies
Legal namestring
Oxford Cannabinoid Technologies Holdings PLC
Websiteurl
oxcantech.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Oxford Cannabinoid Technologies Holdings PLC is a UK-domiciled, publicly listed (LSE: OCTP) clinical-stage biopharmaceutical company founded in 2017 and headquartered in Oxford, England. The company's stated mission is to combine cannabinoid medicine with world-class scientific research, and its disclosed lead asset is OCT130401, a proprietary cannabinoid-based drug candidate positioned for the treatment of trigeminal neuralgia, a severe neuropathic facial pain condition with limited existing therapeutic options.

OCT operates a single-asset, indication-focused R&D model. Its underlying technology is a cannabinoid-based pharmaceutical formulation, with the pipeline concentrated on OCT130401, which is advancing toward a Phase I clinical trial (expected to start in Q2 2024) at a site to be identified in Australia. The company does not disclose pricing, products on market, or commercial customers; the provided financials indicate no reported revenue across FY2021–FY2024, consistent with a pre-commercial posture. Capital has historically been raised through equity rounds (Kingsley Capital Partners in 2017, Casa Verde Capital in 2018) and, most recently, a February 2024 £565,000 convertible loan note with Cantheon Capital LLC alongside existing shareholders and directors to fund the Phase I program.

The company serves the eventual patients and prescribers in the trigeminal neuralgia and broader neuropathic pain space — a market projected to reach $1 billion by 2030 at a 6.4% CAGR — but currently has no paying customers. Leadership comprises CEO John Lucas, founder/co-founder Tarek Tabsh, Executive Chairman Neil Mahapatra, COO and General Counsel Clarissa Sowemimo-Coker, and CSO Valentino Parravicini. With 11–50 employees and a lean capital base, OCT's near-term value creation depends on clinical execution, regulatory milestones, and additional funding rounds.

Short descriptiontext

Oxford Cannabinoid Technologies is a UK-listed clinical-stage biopharmaceutical company developing cannabinoid-based medicines, with lead candidate OCT130401 entering Phase I trials for trigeminal neuralgia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
cannabinoid drug development, neuropathic pain therapeutics, pharmaceutical clinical trials, biopharmaceutical research, trigeminal neuralgia treatment
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Cannabinoid Pharmaceuticals
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Oxford Cannabinoid Technologies is a clinical-stage biopharmaceutical company developing cannabinoid-based prescription medicines. Its lead drug candidate, OCT130401, is being advanced through Phase I clinical trials for the treatment of trigeminal neuralgia, a severe neuropathic facial pain condition with limited existing therapeutic options.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Oxford Cannabinoid Technologies is a biopharmaceutical company developing cannabinoid-based medicines. Its primary product candidate is OCT130401, a treatment for trigeminal neuralgia that has entered Phase I clinical trials. The company is funded through convertible loan agreements while advancing its clinical development program.

Product and service1 record
1OCT130401
Categorydrug candidate
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Jazz acquired GW Pharmaceuticals, the originator of approved cannabinoid medicines Sativex and Epidiolex, and is the most direct comparable for OCT as a cannabinoid-based biopharma developing CNS/neuropathic pain therapies.

TypeDirect peer
Description

Clinical-stage developer of transdermal cannabinoid therapeutics for CNS and pain indications, with a comparable single-asset, indication-focused development model.

3Botanix Pharmaceuticals
TypeDirect peer
Description

Late-clinical-stage cannabinoid pharmaceutical company developing synthetic cannabinoid formulations, overlapping with OCT's botanical-derived cannabinoid drug development strategy.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing cannabinoid-based therapeutics, including candidates in pain and CNS, with a comparable preclinical/early-clinical stage profile.

5Tetra Bio-Pharma
TypeDirect peer
Description

Developer of cannabinoid-derived prescription medicines and synthetic cannabinoid drug candidates, with parallel focus on pain and CNS indications.

TypeEmerging player
Description

Clinical-stage company developing cannabinoid-derived small molecules for CNS and inflammatory conditions, with similar botanical-pharma translation model.

TypeEmerging player
Description

Developer of cannabinoid-based pharmaceutical products targeting pain, neurological, and inflammatory conditions, with comparable pipeline overlap.

TypeEmerging player
Description

Clinical-stage biopharma developing cannabinoid-derived therapeutics, sharing a botanical-cannabinoid drug development thesis with OCT.

TypeBroad incumbent
Description

Established CNS/neuropathic pain incumbent marketing Lyrica; defines the standard-of-care competitive backdrop for any new neuropathic pain entrant.

TypeBroad incumbent
Description

Specialty CNS and pain biopharma developing next-generation neuropathic pain therapies, setting competitive benchmarks for efficacy and safety in the indication OCT is targeting.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oxford Cannabinoid Technologies

Cannabinoid Pharmaceuticalsoxcantech.com

Oxford Cannabinoid Technologies is a UK-listed clinical-stage biopharmaceutical company developing cannabinoid-based medicines, with lead candidate OCT130401 entering Phase I trials for trigeminal neuralgia.

What Oxford Cannabinoid Technologies does

Oxford Cannabinoid Technologies Holdings PLC is a UK-domiciled, publicly listed (LSE: OCTP) clinical-stage biopharmaceutical company founded in 2017 and headquartered in Oxford, England. The company's stated mission is to combine cannabinoid medicine with world-class scientific research, and its disclosed lead asset is OCT130401, a proprietary cannabinoid-based drug candidate positioned for the treatment of trigeminal neuralgia, a severe neuropathic facial pain condition with limited existing therapeutic options.

OCT operates a single-asset, indication-focused R&D model. Its underlying technology is a cannabinoid-based pharmaceutical formulation, with the pipeline concentrated on OCT130401, which is advancing toward a Phase I clinical trial (expected to start in Q2 2024) at a site to be identified in Australia. The company does not disclose pricing, products on market, or commercial customers; the provided financials indicate no reported revenue across FY2021–FY2024, consistent with a pre-commercial posture. Capital has historically been raised through equity rounds (Kingsley Capital Partners in 2017, Casa Verde Capital in 2018) and, most recently, a February 2024 £565,000 convertible loan note with Cantheon Capital LLC alongside existing shareholders and directors to fund the Phase I program.

The company serves the eventual patients and prescribers in the trigeminal neuralgia and broader neuropathic pain space — a market projected to reach $1 billion by 2030 at a 6.4% CAGR — but currently has no paying customers. Leadership comprises CEO John Lucas, founder/co-founder Tarek Tabsh, Executive Chairman Neil Mahapatra, COO and General Counsel Clarissa Sowemimo-Coker, and CSO Valentino Parravicini. With 11–50 employees and a lean capital base, OCT's near-term value creation depends on clinical execution, regulatory milestones, and additional funding rounds.

Oxford Cannabinoid Technologies firmographics

Firmographics
Name
Oxford Cannabinoid Technologies
Legal name
Oxford Cannabinoid Technologies Holdings PLC
Website
https://oxcantech.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Oxford Cannabinoid Technologies is a UK-listed clinical-stage biopharmaceutical company developing cannabinoid-based medicines, with lead candidate OCT130401 entering Phase I trials for trigeminal neuralgia.
Ownership category
akta.pro rank

Oxford Cannabinoid Technologies industry classification

Industry
Product category
Cannabinoid Pharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Cannabinoid drug development
  • Neuropathic pain therapeutics
  • Pharmaceutical clinical trials
  • Biopharmaceutical research
  • Trigeminal neuralgia treatment

Where Oxford Cannabinoid Technologies is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Markets served

Oxford Cannabinoid Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Oxford Cannabinoid Technologies product offering

Product offering

Core offering

Oxford Cannabinoid Technologies is a clinical-stage biopharmaceutical company developing cannabinoid-based prescription medicines. Its lead drug candidate, OCT130401, is being advanced through Phase I clinical trials for the treatment of trigeminal neuralgia, a severe neuropathic facial pain condition with limited existing therapeutic options.

Product overview

Oxford Cannabinoid Technologies is a biopharmaceutical company developing cannabinoid-based medicines. Its primary product candidate is OCT130401, a treatment for trigeminal neuralgia that has entered Phase I clinical trials. The company is funded through convertible loan agreements while advancing its clinical development program.

Differentiator

Problem solved

Functional benefit

Products and services

  • OCT130401

Companies that use Oxford Cannabinoid Technologies

Customer profile

Ideal customer profiles1 record

Oxford Cannabinoid Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Oxford Cannabinoid Technologies partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Oxford Cannabinoid Technologies competitors and assessment

Company assessment

Direct peers

  • Jazz Pharmaceuticals (GW Pharmaceuticals): Jazz acquired GW Pharmaceuticals, the originator of approved cannabinoid medicines Sativex and Epidiolex, and is the most direct comparable for OCT as a cannabinoid-based biopharma developing CNS/neuropathic pain therapies.
  • Zynerba Pharmaceuticals: Clinical-stage developer of transdermal cannabinoid therapeutics for CNS and pain indications, with a comparable single-asset, indication-focused development model.
  • Botanix Pharmaceuticals: Late-clinical-stage cannabinoid pharmaceutical company developing synthetic cannabinoid formulations, overlapping with OCT's botanical-derived cannabinoid drug development strategy.
  • InMed Pharmaceuticals: Clinical-stage biopharmaceutical company developing cannabinoid-based therapeutics, including candidates in pain and CNS, with a comparable preclinical/early-clinical stage profile.
  • Tetra Bio-Pharma: Developer of cannabinoid-derived prescription medicines and synthetic cannabinoid drug candidates, with parallel focus on pain and CNS indications.

Emerging players

  • Emerald Health Pharmaceuticals: Clinical-stage company developing cannabinoid-derived small molecules for CNS and inflammatory conditions, with similar botanical-pharma translation model.
  • Axim Biotechnologies: Developer of cannabinoid-based pharmaceutical products targeting pain, neurological, and inflammatory conditions, with comparable pipeline overlap.
  • Skye Bioscience: Clinical-stage biopharma developing cannabinoid-derived therapeutics, sharing a botanical-cannabinoid drug development thesis with OCT.

Broad incumbents

  • Pfizer (Lyrica/Pregabalin): Established CNS/neuropathic pain incumbent marketing Lyrica; defines the standard-of-care competitive backdrop for any new neuropathic pain entrant.
  • Vertex Pharmaceuticals: Specialty CNS and pain biopharma developing next-generation neuropathic pain therapies, setting competitive benchmarks for efficacy and safety in the indication OCT is targeting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Oxford Cannabinoid Technologies social profiles

Digital presence

Oxford Cannabinoid Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oxford Cannabinoid Technologies leadership team

Management profile

Number of profiles

Profiles5 records

Oxford Cannabinoid Technologies funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oxford Cannabinoid Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford Cannabinoid Technologies

What does Oxford Cannabinoid Technologies do?

Oxford Cannabinoid Technologies is a clinical-stage biopharmaceutical company developing cannabinoid-based prescription medicines. Its lead drug candidate, OCT130401, is being advanced through Phase I clinical trials for the treatment of trigeminal neuralgia, a severe neuropathic facial pain condition with limited existing therapeutic options.

Is Oxford Cannabinoid Technologies a public or private company?

Oxford Cannabinoid Technologies is a public company. It is classified as public and is currently operating.

When was Oxford Cannabinoid Technologies founded?

Oxford Cannabinoid Technologies was founded in 2017. It employs 11 to 50 people.

Where is Oxford Cannabinoid Technologies based?

Oxford Cannabinoid Technologies is headquartered in Oxford, United Kingdom, in the Europe region.

Who are Oxford Cannabinoid Technologies's main competitors?

Direct peers on record are Jazz Pharmaceuticals (GW Pharmaceuticals), Zynerba Pharmaceuticals, Botanix Pharmaceuticals, InMed Pharmaceuticals and Tetra Bio-Pharma. Emerging players are Emerald Health Pharmaceuticals, Axim Biotechnologies and Skye Bioscience. Broad incumbents are Pfizer (Lyrica/Pregabalin) and Vertex Pharmaceuticals.

Does Oxford Cannabinoid Technologies have an API?

No public API is recorded for Oxford Cannabinoid Technologies.

What industry is Oxford Cannabinoid Technologies in?

Oxford Cannabinoid Technologies's product category is Cannabinoid Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIADAA, Pain Relief & Anti-Inflammatory (Analgesics). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
HIT ConsultantOxford Cannabinoid Technologies Achieves “Proof of Concept” for AI-Powered Drug DiscoveryOxford Cannabinoid Technologies announced a proof of concept for its AI-powered drug discovery tool, developed with Hypatia AI. The system analyzes over 30,000 scientific papers against OCT's proprietary library of 500+ cannabinoid derivatives to identify pain medication candidates. The collaboration aims to accelerate development of non-addictive pain drugs.BenzingaSnoop Dogg-Backed Cannabis Biotech Joins Forces With Former Google Experts To Boost AI Drug Discovery - Alphabet (NASDAQ:GOOG)Oxford Cannabinoid Technologies completed proof of concept for its AI-enabled drug discovery asset, developed with Hypatia AI. The tool analyzes 30,000 scientific papers to accelerate discovery of non-addictive cannabinoid-based pain medications. The partnership aims to expand early-stage out-licensing opportunities.LseIN BRIEF: Oxford Cannabinoid agrees GBP565,000 loan notes dealOxford Cannabinoid Technologies Holdings PLC has entered a convertible loan note agreement with Cantheon Capital LLC and existing shareholders to raise up to GBP565,000. The funds will finance phase I trials for its trigeminal neuralgia treatment OCT130401, which are expected to begin in the second quarter of 2024. The transaction is subject to shareholder approval at a general meeting on February 19.Morningstar Financial ResearchIN BRIEF: Oxford Cannabinoid agrees GBP565,000 loan notes dealOxford Cannabinoid Technologies Holdings PLC has entered a convertible loan note agreement with Cantheon Capital LLC and existing shareholders to raise up to GBP565,000. The funds will finance phase I trials for its trigeminal neuralgia treatment OCT130401, which are expected to begin in the second quarter of 2024. The deal requires shareholder approval at a meeting scheduled for February 19.EurolandirConvertible Loan Note AgreementsOxford Cannabinoid Technologies Holdings plc (OCTP) has entered into convertible loan note agreements totaling £565,000 with Cantheon Capital LLC and other investors, aimed at funding its Phase I clinical trial for a new therapy targeting Trigeminal Neuralgia. The investment will occur in two tranches tied to specific operational milestones, with shareholder approval needed for the issuance of new shares. The trial is expected to begin in Q2 2024 in Australia.MarketScreenerOxford Cannabinoid agrees GBP565,000 loan notes dealOxford Cannabinoid Technologies Holdings PLC has entered a convertible loan note agreement with Cantheon Capital LLC and existing shareholders to raise up to GBP565,000. The funds will finance Phase I trials for its trigeminal neuralgia treatment OCT130401, expected to start in Q2 2024, subject to shareholder approval at a meeting on February 19.CityAMLondon’s Oxford Cannabinoid Technologies to launch twin US listingOxford Cannabinoid Technologies is launching a twin listing on the US OTC Equity Market under ticker OCTHF to broaden investor access. The move caused its share price to surge 17.9% by mid-afternoon. Management plans to increase outreach to US-based institutional and retail investors.trib.alSnoop Dogg-Backed Oxford Cannabinoid Fluctuates in DebutOxford Cannabinoid Technologies, a U.K. prescription drug company with Snoop Dogg as an investor, saw its London stock debut with a volatile swing. The stock opened 50% higher, then fell as much as 15%, before trading up 1% at 5.05 pence.CityAMPainkiller maker Oxford Cannabinoid Technologies debuts on London’s marketOxford Cannabinoid Technologies debuted on the London Stock Exchange at 8:00 this morning, offering £0.01 per share. The pre-revenue painkiller maker will receive £14.82m from the IPO to fund pre-clinical development and clinical trials. Its first two drug candidates target about £1.55bn of the £42.5bn pain market, with approval expected by 2027.trib.alSnoop Dogg-Backed Oxford Cannabinoid Looks to List in LondonOxford Cannabinoid Technologies, backed by Snoop Dogg and Imperial Brands, will start trading on the London Stock Exchange on Friday. The company raised 16.5 million pounds ($23 million) in a placing, giving it a market value of about 51.5 million pounds.